Muvalaplin Aces Phase 2 Lp(a) Test
CardiacWire
NOVEMBER 24, 2024
Impressive results from the Phase 2 KRAKEN trial presented at the AHA 2024 Scientific Sessions showed that Eli Lilly’s muvalaplin greatly reduces Lp(a) blood levels, adding an attractive oral option to its Lp(a) pipeline. High Lp(a) is an inherited CVD risk factor that impacts one out of every five people and currently has no approved drug therapies.
Let's personalize your content